$0.30
0.16% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US1407551092
Symbol
CARA
Sector
Industry

Cara Therapeutics Inc Stock price

$0.30
+0.04 13.66% 1M
-0.37 54.62% 6M
-0.44 59.00% YTD
-0.63 67.30% 1Y
-13.04 97.72% 3Y
-24.15 98.75% 5Y
-9.09 96.76% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.00 0.16%
ISIN
US1407551092
Symbol
CARA
Sector
Industry

Key metrics

Market capitalization $16.71m
Enterprise Value $17.17m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.98
P/S ratio (TTM) P/S ratio 1.92
P/B ratio (TTM) P/B ratio 23.63
Revenue growth (TTM) Revenue growth -59.08%
Revenue (TTM) Revenue $8.69m
EBIT (operating result TTM) EBIT $-82.39m
Free Cash Flow (TTM) Free Cash Flow $-77.34m
Cash position $43.54m
EPS (TTM) EPS $-1.75
P/E forward negative
P/S forward 2.37
EV/Sales forward 1.05
Short interest 2.00%
Show more

Is Cara Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Cara Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Cara Therapeutics Inc forecast:

1x Buy
20%
4x Hold
80%

Analyst Opinions

5 Analysts have issued a Cara Therapeutics Inc forecast:

Buy
20%
Hold
80%

Financial data from Cara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
8.69 8.69
59% 59%
100%
- Direct Costs 1.50 1.50
81% 81%
17%
7.18 7.18
46% 46%
83%
- Selling and Administrative Expenses 28 28
10% 10%
326%
- Research and Development Expense 61 61
42% 42%
701%
-82 -82
31% 31%
-945%
- Depreciation and Amortization 0.27 0.27
85% 85%
3%
EBIT (Operating Income) EBIT -82 -82
31% 31%
-948%
Net Profit -96 -96
18% 18%
-1,099%

In millions USD.

Don't miss a Thing! We will send you all news about Cara Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cara Therapeutics Inc Stock News

Negative
InvestorPlace
6 months ago
Cara Therapeutics (NASDAQ: CARA ) stock is falling hard on Thursday after the development-stage biopharmaceutical company announced new data from a clinical trial. This data comes from the company's Part A KOURAGE-1 study.
Negative
Reuters
6 months ago
Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental drug did not demonstrate a meaningful clinical benefit compared to placebo.
Neutral
GlobeNewsWire
6 months ago
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from p...

Company Profile

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Head office United States
CEO Christopher Posner
Employees 55
Founded 2004
Website www.caratherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today